Latazed

Latanoprost, the active ingredient in Latazed, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latazed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance and reliable global logistics for this EU‑approved ophthalmic product. Clients benefit from consistent batch release testing and traceability throughout the supply chain.

Latazed (latanoprost) acts on the prostaglandin pathway to reduce intra‑ocular pressure in glaucoma‑related conditions.

- Open-angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: lowers elevated eye pressure to prevent progression to glaucoma. - Elevated intra‑ocular pressure: decreases pressure to protect visual function.

Latazed may cause ocular and systemic adverse reactions, which are categorized by frequency.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye itching: pruritus of the peri‑ocular area. - Increased brown pigmentation of the iris: gradual darkening. - Eyelash growth: longer, thicker lashes.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract. - Severe allergic reaction: swelling, rash, or anaphylaxis.

When prescribing Latazed, clinicians should observe the following precautions to ensure safe use.

- Monitor intra‑ocular pressure: verify adequate pressure reduction after initiation. - Assess for ocular inflammation: avoid use in active uveitis or ocular infection. - Evaluate corneal health: discontinue if corneal edema develops. - Consider systemic conditions: use cautiously in patients with asthma or cardiovascular disease. - Store at room temperature: keep below 25 °C, protect from light and moisture in original container.

Latazed can interact with other ophthalmic or systemic agents; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Prostaglandin analogs combined: may cause additive ocular irritation. - Carbonic anhydrase inhibitors: potential for excessive intra‑ocular pressure reduction.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: monitor for additive pressure‑lowering effect. - Non‑steroidal anti‑inflammatory eye drops: may increase risk of ocular inflammation. - Systemic NSAIDs: observe for possible enhancement of prostaglandin effects.